We Give Our Utmost Care to 

Better Safeguard Patients’ Health

Our Dedication to Patients is Reflected in Every Detail in Manufacturing and Operations


Global Heparin Industrial Chain

Hepalink is a leader in the heparin industrial chain segment and one of a few biopharmaceutical companies with vertically integrated capabilities covering the entire heparin industrial chain

All of Hepalink’s enoxaparin sodium preparations are made of the company’s own heparin APIs, and are completely traceable

Enoxaparin sodium preparation's approved indications in China
Prophylaxis of VTE diseases:
· Prophylaxis of VTE in total hip arthroplasty (THA)
· Prophylaxis of VTE in total knee arthroplasty (TKA)
· Prophylaxis of VTE in orthopedic trauma
· Prophylaxis of VTE in pelvic surgery
· Prophylaxis of VTE in general surgery
· Prophylaxis of VTE in medical treatment
Treatment of existing DVT:
· Anticoagulant treatment of DVT with or without pulmonary embolism
Prophylaxis of VTE
Anticoagulant in ACS treatment
Treatment of VTE
Anticoagulant in hemodialysis
Enoxaparin sodium injection

1 drug adopted for treatment in

4 therapeutic areas

NSTE-ACS:
· Anticoagulant in the treatment of unstable angina / non-Q wave myocardial infarction
· Anticoagulant in PCI treatment
STEMI:
· Anticoagulant in the medical treatment of STEMI
· Anticoagulant in PCI treatment
Hemodialysis:
· Prevention of thrombosis in the extra-corporeal circulation of hemodialysis
VTE:venous thromboembolism DVT:deep venous thrombosis NSTE-ACS:Non-ST elevation-acute coronary syndrome STEMI:ST-segment elevation myocardial infarction PCI:percutaneous coronary intervention
Clinical applications and guideline recommendations of enoxaparin preparations
Respiratory Diseases
Therapeutic Advantage and Guideline Recommendation

·ACC9 Guideline

·Recommended by the China Guideline issued in 2015

·6-14 days of prophylaxis (LMWH/LDUH/mechanical prophylaxis) in hospitalized high VTE risk patients with a Padua score≥4

Patients with following underlying risk factors:

Varicosity, chronic heart failure, malignant tumor, hemiparesis, prior VTE, or aged>75yrs;

and

·acute myocardial infarction with high risk of VTE

·Transient ischemic attack

·Acute/severe chronic obstructive pulmonary disease patients who are bedridden or with infections, polycythemia, hard-to-treat heart failure, or in need of non-invasive or Invasive mechanical ventilation due to respiratory failure

·High VTE risk patients in ICU

COVID-19 Infections
Therapeutic Advantage and Guideline Recommendation

·WHO recommendations for the prevention of VTE associated with COVID-19 infections

·Patients with COVID-19 infection and concomitant VTE

Cardiology
Therapeutic Advantage and Guideline Recommendation

·2014 AHA and ACS Guidelines

·2018 ECS Guideline

·2020 Guideline for the primary care of patients with STEMI

·Chinese expert’s consensus on the use of enoxaparin for anticoagulation in patients with ACS

·The TIMI 11B study

Patients with ACS with or without prior PCI treatment

·Non-ST elevation-acute coronary syndrome (NSTE-ACS)

·Unstable angina (UA)

·ST-segment elevation myocardial infarction (STEMI)

Internal Medicine
Therapeutic Advantage and Guideline Recommendation

·The 2015 guideline issued in China recommends 6-14 days of prophylaxis (LMWH/LDUH/mechanical VTE prophylaxis) in hospitalized high VTE-risk patients with a Padua score≥4

Hospitalized patients with high VTE risk

·Patients with acute myocardial infarction and high risk of VTE

·Transient ischemic attack patients

·Acute/severe chronic obstructive pulmonary disease patients who are bedridden or with infections, polycythemia, hard-to-treat heart failure, or in need of non-invasive or Invasive mechanical ventilation due to respiratory failure

·High VTE risk patients in ICU

Neurology
Therapeutic Advantage and Guideline Recommendation

·2015 consensus on the comprehensive prevention of thrombosis: patients with TIA should be considered for LMWH treatment as early as possible. The consensus also recommends to combine LMWH with mechanical VTE prophylaxis

·Transient ischemic attack (TIA)

Gynecology and obstetrics / reproductive health*
Therapeutic Advantage and Guideline Recommendation

·ACOG Guidelines: LMWH is the preferred anticoagulant for the prevention of thrombosis during pregnancy

·Enoxaparin does not cross the placenta, is therefore safer to the pregnant woman and the fetus

·Meta-analysis showed that LMWH can improve the rate of live birth and reduce abortion

·Chinese Experts’ Consensus on the Use of LMWH in the Prevention of Spontaneous Abortions has commended LMWH in the prevention and treatment of RSA patients with PTS, APS, or AID etc**.

** RSA, recurrent spontaneous abortion. PTS, postthrombotic syndrome. APS, antiphospholipid antibody syndrome. AID, autoimmune disorder

·Pregnant patients with acute VTE or prior VTE

·C-section patients, especially those with obesity, gestational diabetes, gestational hypertension, gemellary pregnancy, or prior c-section

·Potential application in the treatment of patients with recurrent spontaneous abortion (RSA)

*Only use enoxaparin during pregnancy when doctors deem it necessary. Please see Prolongin® product insert for more information.

Burns and vascular surgery
Therapeutic Advantage and Guideline Recommendation

·Based on Caprini risk modeling, Guideline recommends LMWH as anticoagulant in surgical patients with mid/high VTE risk (Caprini score >3)

·Burn patients and patients receiving surgical treatment

Orthopedics
Therapeutic Advantage and Guideline Recommendation

·Patients undergoing major orthopedic surgeries require routine prophylaxis of VTE that should be determined by the VTE risk score

·Medicinal prophylaxis is required in patients with Caprini score ≥2

·Enoxaparin can significantly reduce the incidence of DVT and PTE without increasing the risk of excessive bleeding in patients who received major orthopedic surgeries

Patients receiving major orthopedic surgeries such as

·Total hip arthroplasty (THA)

·Total knee arthroplasty (TKA)

·Hip fracture surgery (HFS)

·Femoral neck, Intertrochanteric, or subtrochanteric fixations

Patients with orthopedic injuries
Cancer
Therapeutic Advantage and Guideline Recommendation

·ASCO, ESMO, NCCN, and BJH Guidelines

·Prevention and treatment of VTE in cancer patients

Surgery
Therapeutic Advantage and Guideline Recommendation

·The 2016 ACCP guideline for the prevention of VTE in non-orthopedic surgical patients recommends LMWH for anticoagulation in surgical patients with mid/high VTE risks (Caprini score>3)

·Mid/High-risk surgical patients and high-risk surgical patients with abdominal / pelvic tumor (Caprini score≥3)